Evaluation of A549 as a New Vaccine Cell Substrate: Digging Deeper with Massively Parallel Sequencing

References

1. 1.↵
   1. Graham F. L.,
   2. Smiley J.,
   3. Russell W. C.,
   4. Nairn R.

   Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36 (1), 59–74.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   FDA. Guidance for Industry Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications; OVRR, Ed.; FDA: Rockville, MD, 2010.
3. 3.↵
   FDA. Cell Lines Derived from Human Tumors for Vaccine Manufacture. In VRBPAC September 2012; FDA: Silver Spring, MD, 2012.
4. 4.↵
   1. Sheng-Fowler L.,
   2. Lewis A. M. Jr..,
   3. Peden K.

   Issues associated with residual cell-substrate DNA in viral vaccines. Biologicals 2009, 37 (3), 190–195.

   OpenUrlPubMed
5. 5.↵
   Laboratory Animal Welfare Act, In Code of Federal Regulations, 1966.
6. 6.↵
   1. Khan A. S.,
   2. Ma W.,
   3. Ma Y.,
   4. Kumar A.,
   5. Williams D. K.,
   6. Muller J.,
   7. Ma H.,
   8. Galvin T. A.

   Proposed algorithm to investigate latent and occult viruses in vaccine cell substrates by chemical induction. Biologicals 2009, 37 (3), 196–201.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Giard D. J.,
   2. Aaronson S. A.,
   3. Todaro G. J.,
   4. Arnstein P.,
   5. Kersey J. H.,
   6. Dosik H.,
   7. Parks W. P.

   In vitro cultivation of human tumors: Establishment of cell lines derived from a series of solid tumors. J. Natl Cancer Inst. 1973, 51 (5), 1417–1423.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Massion P. P.,
   2. Zou Y.,
   3. Chen H.,
   4. Jiang A.,
   5. Coulson P.,
   6. Amos C. I.,
   7. Wu X.,
   8. Wistuba I.,
   9. Wei Q.,
   10. Shyr Y.,
   11. Spitz M. R.

   Smoking-related genomic signatures in non-small cell lung cancer. 2008, 178 (11), 1164–1172.
9. 9.↵
   1. Ding L.,
   2. Getz G.,
   3. Wheeler D. A.,
   4. Mardis E. R.,
   5. McLellan M. D.,
   6. Cibulskis K.,
   7. Sougnez C.,
   8. Greulich H.,
   9. Muzny D. M.,
   10. Morgan M. B.,
   11. Fulton L.,
   12. Fulton R. S.,
   13. Zhang Q.,
   14. Wendl M. C.,
   15. Lawrence M. S.,
   16. Larson D. E.,
   17. Chen K.,
   18. Dooling D. J.,
   19. Sabo A.,
   20. Hawes A. C.,
   21. Shen H.,
   22. Jhangiani S. N.,
   23. Lewis L. R.,
   24. Hall O.,
   25. Zhu Y.,
   26. Mathew T.,
   27. Ren Y.,
   28. Yao J.,
   29. Scherer S. E.,
   30. Clerc K.,
   31. Metcalf G. A.,
   32. Ng B.,
   33. Milosavljevic A.,
   34. Gonzalez-Garay M. L.,
   35. Osborne J. R.,
   36. Meyer R.,
   37. Shi X.,
   38. Tang Y.,
   39. Koboldt D. C.,
   40. Lin L.,
   41. Abbott R.,
   42. Miner T. L.,
   43. Pohl C.,
   44. Fewell G.,
   45. Haipek C.,
   46. Schmidt H.,
   47. Dunford-Shore B. H.,
   48. Kraja A.,
   49. Crosby S. D.,
   50. Sawyer C. S.,
   51. Vickery T.,
   52. Sander S.,
   53. Robinson J.,
   54. Winckler W.,
   55. Baldwin J.,
   56. Chirieac L. R.,
   57. Dutt A.,
   58. Fennell T.,
   59. Hanna M.,
   60. Johnson B. E.,
   61. Onofrio R. C.,
   62. Thomas R. K.,
   63. Tonon G.,
   64. Weir B. A.,
   65. Zhao X.,
   66. Ziaugra L.,
   67. Zody M. C.,
   68. Giordano T.,
   69. Orringer M. B.,
   70. Roth J. A.,
   71. Spitz M. R.,
   72. Wistuba I. I.,
   73. Ozenberger B.,
   74. Good P. J.,
   75. Chang A. C.,
   76. Beer D. G.,
   77. Watson M. A.,
   78. Ladanyi M.,
   79. Broderick S.,
   80. Yoshizawa A.,
   81. Travis W. D.,
   82. Pao W.,
   83. Province M. A.,
   84. Weinstock G. M.,
   85. Varmus H. E.,
   86. Gabriel S. B.,
   87. Lander E. S.,
   88. Gibbs R. A.,
   89. Meyerson M.,
   90. Wilson R. K.

   Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455 (7216), 1069–1075.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    NCI. Harms of smoking and health benefits of quitting. 2012. Available from: http://www.cancer.gov/cancertopics/factsheet/Tobacco/cessation.
11. 11.↵
    1. Weir B. A.,
    2. Woo M. S.,
    3. Getz G.,
    4. Perner S.,
    5. Ding L.,
    6. Beroukhim R.,
    7. Lin W. M.,
    8. Province M. A.,
    9. Kraja A.,
    10. Johnson L. A.,
    11. Shah K.,
    12. Sato M.,
    13. Thomas R. K.,
    14. Barletta J. A.,
    15. Borecki I. B.,
    16. Broderick S.,
    17. Chang A. C.,
    18. Chiang D. Y.,
    19. Chirieac L. R.,
    20. Cho J.,
    21. Fujii Y.,
    22. Gazdar A. F.,
    23. Giordano T.,
    24. Greulich H.,
    25. Hanna M.,
    26. Johnson B. E.,
    27. Kris M. G.,
    28. Lash A.,
    29. Lin L.,
    30. Lindeman N.,
    31. Mardis E. R.,
    32. McPherson J. D.,
    33. Minna J. D.,
    34. Morgan M. B.,
    35. Nadel M.,
    36. Orringer M. B.,
    37. Osborne J. R.,
    38. Ozenberger B.,
    39. Ramos A. H.,
    40. Robinson J.,
    41. Roth J. A.,
    42. Rusch V.,
    43. Sasaki H.,
    44. Shepherd F.,
    45. Sougnez C.,
    46. Spitz M. R.,
    47. Tsao M. S.,
    48. Twomey D.,
    49. Verhaak R. G.,
    50. Weinstock G. M.,
    51. Wheeler D. A.,
    52. Winckler W.,
    53. Yoshizawa A.,
    54. Yu S.,
    55. Zakowski M. F.,
    56. Zhang Q.,
    57. Beer D. G.,
    58. Wistuba I. I.,
    59. Watson M. A.,
    60. Garraway L. A.,
    61. Ladanyi M.,
    62. Travis W. D.,
    63. Pao W.,
    64. Rubin M. A.,
    65. Gabriel S. B.,
    66. Gibbs R. A.,
    67. Varmus H. E.,
    68. Wilson R. K.,
    69. Lander E. S.,
    70. Meyerson M.

    Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450 (7171), 893–898.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Fukumoto S.,
    2. Yamauchi N.,
    3. Moriguchi H.,
    4. Hippo Y.,
    5. Watanabe A.,
    6. Shibahara J.,
    7. Taniguchi H.,
    8. Ishikawa S.,
    9. Ito H.,
    10. Yamamoto S.,
    11. Iwanari H.,
    12. Hironaka M.,
    13. Ishikawa Y.,
    14. Niki T.,
    15. Sohara Y.,
    16. Kodama T.,
    17. Nishimura M.,
    18. Fukayama M.,
    19. Dosaka-Akita H.,
    20. Aburatani H.

    Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin. Cancer Res. 2005, 11 (5), 1776–1185.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Rodriguez-Nieto S.,
    2. Sanchez-Cespedes M.

    BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer. Carcinogenesis 2009, 30 (4), 547–554.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Wingo S. N.,
    2. Gallardo T. D.,
    3. Akbay E. A.,
    4. Liang M. C.,
    5. Contreras C. M.,
    6. Boren T.,
    7. Shimamura T.,
    8. Miller D. S.,
    9. Sharpless N. E.,
    10. Bardeesy N.,
    11. Kwiatkowski D. J.,
    12. Schorge J. O.,
    13. Wong K. K.,
    14. Castrillon D. H.

    Somatic LKB1 mutations promote cervical cancer progression. PLoS ONE 2009, 4 (4), 5137.

    OpenUrl
15. 15.↵
    1. Rudin C. M.,
    2. Avila-Tang E.,
    3. Harris C. C.,
    4. Herman J. G.,
    5. Hirsch F. R.,
    6. Pao W.,
    7. Schwartz A. G.,
    8. Vahakangas K. H.,
    9. Samet J. M.

    Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin. Cancer Res. 2009, 15 (18), 5646–5461.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    Welcome Trust Sanger Institute. NCI-60 Cancer Gene Cell Line Project. 2012. Available at: http://www.sanger.ac.uk/perl/genetics/CGP/core_line_viewer?action=sample&id=905949.
17. 17.↵
    Wellcome Trust Sanger Institute database of somatic mutation information in human cancers. 2012.
18. 18.↵
    1. Loeb K. A.,
    2. Loeb L. A.

    Significance of multiple mutations in cancer. Carcinogenesis 2000, 21 (3), 379–385.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Frisch S. M.

    Anoikis. Methods Enzymol. 2000, 322, 472–479.

    OpenUrlPubMedWeb of Science
20. 20.↵
    1. Feng H.,
    2. Shuda M.,
    3. Chang Y.,
    4. Moore P. S.

    Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319 (5866), 1096–1100.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Chuck A. S.,
    2. Clarke M. F.,
    3. Palsson B. O.

    Retroviral infection is limited by Brownian motion. Hum Gene Ther. 1996, 7 (13), 1527–1534.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Curiel D.,
    2. Douglas J.

    1. Evans J.,
    2. Hearing P.

    Adenovirus Replication. In Adenoviral Vectors for Gene Thereapy, Curiel D., Douglas J. , Eds.; Academic Press: San Diego, CA, 2002.
23. 23.↵
    1. Gu J.,
    2. Zhang L.,
    3. Swisher S. G.,
    4. Liu J.,
    5. Roth J. A.,
    6. Fang B.

    Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. Oncogene 2004, 23 (6), 1300–1307.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Onions D.,
    2. Kolman J.

    Massively parallel sequencing, a new method for detecting adventitious agents. Biologicals 2010, 38 (3), 377–380.

    OpenUrlPubMed
25. 25.↵
    1. Kolman J.

    Personal communication, 2013.
26. 26.↵
    1. Souza T. A.,
    2. Stollar B. D.,
    3. Sullivan J. L.,
    4. Luzuriaga K.,
    5. Thorley-Lawson D. A.

    Influence of EBV on the peripheral blood memory B cell compartment. J. Immunol. 2007, 179 (5), 3153–3160.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Minarovits J.

    Epigenotypes of latent herpesvirus genomes. Curr. Top. Microbiol. Immunol. 2006, 310, 61–80.

    OpenUrlPubMedWeb of Science
28. 28.↵
    1. Mayall T.

    A novel cell substrate enabling production of new vaccine candidates. 2012. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM325115.pptx.
29. 29.↵
    FDA. Summary Minutes Vaccines and Related Biological Products Advisory Committee September 19, 2012, in Vaccine and Realted Biological Products Advisory Products Committee Meeting September 2012. FDA: Silver Spring, MD, 2012.
30. 30.↵
    1. Skloot R.

    The Immortal Life of Henrietta Lacks; Broadway Paperbacks: New York, 2011; p 381.
31. 31.↵
    1. Peden K.,
    2. Sheng L.,
    3. Pal A.,
    4. Lewis A.

    Biological activity of residual cell-substrate DNA. Dev. Biol. (Basel) 2006, 123, 45–53, discussion 55–73.

    OpenUrlPubMed
32. 32.↵
    FDA. FDA Briefing Document, Sept 19, 2012.